Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Wednesday

Chemomab Therapeutics (NASDAQ:CMMB) is expected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Chemomab Therapeutics to post earnings of ($0.04) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 21, 2026 at 12:30 PM ET.

Chemomab Therapeutics (NASDAQ:CMMB) last released its earnings results on Thursday, March 19th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). On average, analysts expect Chemomab Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chemomab Therapeutics Stock Performance

NASDAQ:CMMB opened at $1.77 on Friday. The stock has a fifty day moving average price of $1.71 and a 200-day moving average price of $1.99. The company has a market cap of $12.73 million, a price-to-earnings ratio of -0.69 and a beta of 0.51. Chemomab Therapeutics has a fifty-two week low of $1.35 and a fifty-two week high of $5.88.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. ADAR1 Capital Management LLC bought a new stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $132,000. ADAR1 Capital Management LLC owned 1.30% of Chemomab Therapeutics as of its most recent filing with the Securities and Exchange Commission. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.